{"nctId":"NCT02273050","briefTitle":"Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Drug Naive Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control","startDateStruct":{"date":"2014-12"},"conditions":["Type 2 Diabetes Mellitus"],"count":1136,"armGroups":[{"label":"Saxagliptin 5 mg + Metformin (500 mg with titration)","type":"EXPERIMENTAL","interventionNames":["Drug: Saxagliptin 5 mg","Drug: Metformin 500 mg with titration"]},{"label":"Saxagliptin 5 mg + Placebo","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Saxagliptin 5 mg","Drug: Placebo 500 mg for metformin (with titration)"]},{"label":"Metformin (500 mg with titration) + Placebo","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Placebo 5 mg for Saxagliptin","Drug: Metformin 500 mg with titration"]}],"interventions":[{"name":"Saxagliptin 5 mg","otherNames":["Onglyza","BMS-477118"]},{"name":"Placebo 5 mg for Saxagliptin","otherNames":[]},{"name":"Placebo 500 mg for metformin (with titration)","otherNames":[]},{"name":"Metformin 500 mg with titration","otherNames":["Glucophage"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1\\. Subjects with type 2 diabetes mellitus; 2. HbA1c ≥8% but ≤12%; 3.Fasting C-peptide ≥1.0 ng/ml; 4. Subject will be drug naïve; 5. Body mass index ≤40 kg/m2.\n\nExclusion Criteria:\n\n1\\. Symptoms of poorly controlled diabetes; 2. Chronic or repeated intermittent corticosteroid treatment ; 3. Calculated creatinine clearance \\<60 ml/min or serum creatinine \\>132.6 μmol/L (\\>1.5 mg/dL) for men, \\>123.8 μmol/L (\\>1.4 mg/dL) for women; 4. Creatine Kinase ≥3x ULN; 5.Abnormal TSH value at screening will be further evaluated by free T4, subjects with an abnormal free T4 will be excluded; 6. History of administration of any antihyperglycaemic therapy for a total of 28 days or for more than three consecutive days or a total of seven non-consecutive days during the eight weeks prior to screening; 7. Current treatment with a strong CYP3A4/5 inhibitor; 8. Prior treatment with saxagliptin or any DPP-4 inhibitor; 9. Significant or history of cardiovascular disease, renal disease, psychiatric disorders, Immunocompromised individuals, hemoglobinopathies, liver disease, Pancreatitis.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"100 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in HbA1c From Baseline to Week 24 Provided That it is Prior to Rescue","description":"To evaluate the efficacy of the combination therapy (saxagliptin + metformin) when compared to placebo + metformin and placebo + saxagliptin with respect to reduction in HbA1c (%) at the end of 24 weeks of double-blinded treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.007","spread":"0.0706"},{"groupId":"OG001","value":"-2.123","spread":"0.0701"},{"groupId":"OG002","value":"-2.794","spread":"0.0715"}]}]}]},{"type":"SECONDARY","title":"Glycemic Response Defined as HbA1c < 7.0% at Week 24","description":"To evaluate the efficacy of the combination therapy (saxagliptin + metformin) when compared to placebo + metformin and placebo + saxagliptin with respect to the proportion of subjects achieving a therapeutic glycemic response defined as HbA1c \\< 7.0% at the end of 24 weeks of double-blinded treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81.8","spread":null},{"groupId":"OG001","value":"44.3","spread":null},{"groupId":"OG002","value":"71.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 24 (Prior to Rescue) in Fasting Plasma Glucose","description":"To evaluate the efficacy of the combination therapy (saxagliptin + metformin) when compared to placebo + metformin and placebo + saxagliptin with respect to reduction in fasting plasma glucose at the end of 24 weeks of double-blinded treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.25","spread":"0.112"},{"groupId":"OG001","value":"-1.86","spread":"0.111"},{"groupId":"OG002","value":"-2.94","spread":"0.113"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 24 (Prior to Rescue) in Area Under the Curve From 0-180 Minutes for Postprandial Glucose Response to a Meal Tolerance Test","description":"To evaluate the efficacy of the combination therapy (saxagliptin + metformin) when compared to placebo + metformin and placebo + saxagliptin with respect to change in 180-minute postprandial glucose response to a meal tolerance test at the end of 24 weeks of double-blinded treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1027.8","spread":"36.22"},{"groupId":"OG001","value":"-611.9","spread":"36.69"},{"groupId":"OG002","value":"-858.5","spread":"37.36"}]}]}]},{"type":"SECONDARY","title":"Glycemic Response Defined as HbA1c ≤ 6.5% at Week 24","description":"To evaluate the efficacy of the combination therapy (saxagliptin + metformin) when compared to placebo + metformin and placebo + saxagliptin with respect to the proportion of subjects achieving a therapeutic glycemic response defined as HbA1c ≤ 6.5% at the end of 24 weeks of double-blinded treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.0","spread":null},{"groupId":"OG001","value":"32.1","spread":null},{"groupId":"OG002","value":"55.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 24 in 120-minute Postprandial Glucose Response to a Meal Tolerance Test","description":"To evaluate the efficacy of the combination therapy (saxagliptin + metformin) when compared to placebo + metformin and placebo + saxagliptin with respect to change in 120-minute postprandial glucose response to a meal tolerance test at the end of 24 weeks of double-blinded treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.09","spread":"0.261"},{"groupId":"OG001","value":"-4.12","spread":"0.262"},{"groupId":"OG002","value":"-5.95","spread":"0.268"}]}]}]},{"type":"SECONDARY","title":"Patients Rescued for Failing to Achieve Pre-specified Glycemic Targets or Discontinuation for Lack of Efficacy During the 24-week Double-blind Treatment Phase","description":"To evaluate the efficacy of the combination therapy (saxagliptin + metformin) when compared to placebo + metformin and placebo + saxagliptin with respect to the proportion of subjects requiring rescue for failing to achieve pre-specified glycemic targets or discontinuing for lack of efficacy within the 24 weeks of double-blinded treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":null},{"groupId":"OG001","value":"10.3","spread":null},{"groupId":"OG002","value":"1.4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":210},"commonTop":["Upper respiratory tract infection","Diarrhoea","Hyperlipidaemia"]}}}